| Multiple Myeloma
Tecvayli vs Velcade
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Tecvayli vs Velcade with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVelcade has a higher rate of injection site reactions vs Tecvayli based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Velcade but not Tecvayli, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tecvayli
Velcade
At A Glance
SC injection
Weekly to every 4 weeks
BCMA-directed CD3 T-cell engager
SC or IV injection
Twice weekly
Proteasome inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
- Carcinoma in situ of other and unspecified small intestine NOS
Dosing
Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.
Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.
Multiple Myeloma 1.3 mg/m2 SC or IV; previously untreated: twice weekly (Days 1, 4, 8, 11) in cycles 1-4 then once weekly (Days 1, 8, 22, 29) in cycles 5-9 with melphalan and prednisone for 9 six-week cycles; relapsed: twice weekly (Days 1, 4, 8, 11) every 3 weeks as single agent or with dexamethasone.
Carcinoma in situ of other and unspecified small intestine NOS 1.3 mg/m2 IV twice weekly (Days 1, 4, 8, 11) for 2 weeks followed by a 10-day rest period, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) for 6 three-week cycles.
Contraindications
—
- Hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions
- Intrathecal administration
Adverse Reactions
Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased
Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy
Most common (>=10%) Nausea, diarrhea, fatigue, peripheral neuropathies, thrombocytopenia, vomiting, constipation, pyrexia, anorexia, anemia, headache, neutropenia, rash, paresthesia, dizziness, weakness
Serious Diarrhea, vomiting, pyrexia, nausea, dehydration, thrombocytopenia, pneumonia, dyspnea, peripheral neuropathies, herpes zoster
Postmarketing Cardiac tamponade, bilateral deafness, optic neuropathy, blindness, ischemic colitis, progressive multifocal leukoencephalopathy, herpes meningoencephalitis, posterior reversible encephalopathy syndrome, Guillain-Barre syndrome, demyelinating polyneuropathy, acute diffuse infiltrative pulmonary disease, Stevens-Johnson syndrome/toxic epidermal necrolysis, acute febrile neutrophilic dermatosis
Pharmacology
Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells; inhibition of this pathway disrupts homeostatic proteolysis, affecting multiple signaling cascades and leading to cell death in various cancer cell types including multiple myeloma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tecvayli
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Velcade
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Tecvayli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Velcade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tecvayli
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Velcade
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
J&J withMe Savings Program: TecvayliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Velcade.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TecvayliView full Tecvayli profile
VelcadeView full Velcade profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.